ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Photothermal-Responsive PRP-Loaded Hydrogel Engineered With Composite Nanobottle for Controllable Delivery of Growth Factors and Multifunctional Therapy of Diabetic Wounds.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Infection Control to Tissue Regeneration: Mechanisms, Design Strategies, and Smart Advances in Antibacterial Hydrogels.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In this paper, we develop a photothermal-responsive hydrogel (CNB-ePRP) based on engineered platelet-rich plasma (PRP)/sodium alginate (SA) hydrogel integrating thrombin-functionalized composite nanobottle (CNB) to treat diabetic wounds. Within CNB-ePRP, the CNB consists of polydopamine nanobottle loaded with thrombin, personalized drugs and a phase-change material. As a photothermal agent and dual-stage controller, CNB not only enables in situ PRP activation at physiological temperature to slowly release various growth factors (GFs) via thermal-triggered thrombin release, avoiding premature burst release of GFs, but also accelerates the release of GFs from the CNB-ePRP hydrogel through mild photothermal heating under 808 nm laser irradiation. Meanwhile, SA enhances hydrogel stability and prolongs GF release kinetics. Consequently, CNB-ePRP achieves on-demand delivery of GFs, significantly promoting angiogenesis, cell proliferation and M2 macrophage polarization. Moreover, CNB-ePRP can mitigate oxidative stress via the antioxidant activity of CNB. Furthermore, vancomycin is loaded into CNB to construct a multimodal antimicrobial hydrogel (VCNB-ePRP) that combines antibiotic and photothermal therapy to efficiently eradicate MRSA and promote healing in MRSA-infected diabetic mouse wounds. Collectively, this study offers a smart PRP-derived platform, characterized by in situ PRP activation, on-demand GFs release, personalized antimicrobial loading and multifunctional therapy, for managing diabetic wounds with great translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.